LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

Dual intracavitary therapy for pleural infections: leaving reluctance behind

Photo from archive.org

The optimal management of complicated parapneumonic effusions and empyemas remains undefined. Over the past two decades, three guidelines from scientific societies have been developed to aid treatment selection in this… Click to show full abstract

The optimal management of complicated parapneumonic effusions and empyemas remains undefined. Over the past two decades, three guidelines from scientific societies have been developed to aid treatment selection in this setting [1–3]. In 2000, the American College of Chest Physicians stated that intrapleural fibrinolytics, video-assisted thoracoscopic surgery (VATS) and surgery (thoracotomy with or without decortication) were all acceptable approaches for managing patients who meet any of the following characteristics [1]: pus (category 4 effusions or, strictly speaking, empyemas), large (at least half of the hemithorax) or loculated effusions, positive pleural fluid cultures or Gram stains, or a fluid pH <7.20 (the last three conditions integrating category 3 effusions). Intrapleural tPA/DNase therapy is cost-effective for the management of complicated parapneumonic effusions and empyemas http://bit.ly/2Lv0Kg9

Keywords: intracavitary therapy; pleural infections; dual intracavitary; therapy pleural; therapy; infections leaving

Journal Title: European Respiratory Journal
Year Published: 2019

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.